Search results

Articles (5)

Journals (0)

1-5 of 5 results for KEYNOTE 522

Sort by:

Relevance

Select all

Sort by:

Relevance

Restricted accessResearch articleFirst published 2025

Safety and tolerability of adjuvant combination treatments following KEYNOTE-522 for early-stage or locally advanced breast cancer with residual disease

Julie Lyon Boucher, Katie Lynn Konieczny, Blerina Mukallari [...]

Journal of Oncology Pharmacy Practice

Open accessCase reportFirst published March, 2023

KEYNOTE—522 and male spindle cell carcinoma of the breast: A case report

Harper E Niver, Edward Foxhall, Anup Lahiry

Rare Tumors

Open accessReview articleFirst published 2022

Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches,Efficacy,and Challenges

Katarzyna Uchimiak, Anna M. Badowska-Kozakiewicz, Aleksandra Sobiborowicz-Sadowska [...]

Clinical Medicine Insights: Oncology

Restricted accessReview articleFirst published 2026

Efficacy and safety of adjuvant capecitabine and pembrolizumab in early-stage triple-negative breast cancer after standard neo-/adjuvant chemotherapy: A meta-analysis of phase III studies

Wala Ben Kridis, Afef Khanfir

Journal of Oncology Pharmacy Practice

Open accessReview articleFirst published September, 2025

Clinical Management in BRCA Carriers with Early Breast Cancer

Bruno Muñante, Roberto Paz-Manrique, Joseph A. Pinto [...]

Cancer Control

Search results

Articles (5)

Journals (0)

1-5 of 5 results for KEYNOTE 522

Sort by:

Relevance

Select all

Sort by:

Relevance

Restricted accessResearch articleFirst published 2025

Safety and tolerability of adjuvant combination treatments following KEYNOTE-522 for early-stage or locally advanced breast cancer with residual disease

Julie Lyon Boucher, Katie Lynn Konieczny, Blerina Mukallari [...]

Journal of Oncology Pharmacy Practice

Open accessCase reportFirst published March, 2023

KEYNOTE—522 and male spindle cell carcinoma of the breast: A case report

Harper E Niver, Edward Foxhall, Anup Lahiry

Rare Tumors

Open accessReview articleFirst published 2022

Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches,Efficacy,and Challenges

Katarzyna Uchimiak, Anna M. Badowska-Kozakiewicz, Aleksandra Sobiborowicz-Sadowska [...]

Clinical Medicine Insights: Oncology

Restricted accessReview articleFirst published 2026

Efficacy and safety of adjuvant capecitabine and pembrolizumab in early-stage triple-negative breast cancer after standard neo-/adjuvant chemotherapy: A meta-analysis of phase III studies

Wala Ben Kridis, Afef Khanfir

Journal of Oncology Pharmacy Practice

Open accessReview articleFirst published September, 2025

Clinical Management in BRCA Carriers with Early Breast Cancer

Bruno Muñante, Roberto Paz-Manrique, Joseph A. Pinto [...]

Cancer Control